COVID-19 pandemic: An innovative, safe and effective bio-decontamination technology for non-toxic removal of biological agents, including coronavirus

Información del proyecto

ABwipe

Identificador del acuerdo de subvención: 959436

DOI

10.3030/959436

Proyecto cerrado

Fecha de la firma de la CE 27 Julio 2020

Fecha de inicio 1 Agosto 2020

Fecha de finalización 31 Enero 2023

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 2 772 812,50

Aportación de la UE

€ 1 940 968,75

Coordinado por

AQUILA BIOSCIENCE LIMITED
Ireland

Periodic Reporting for period 2 - ABwipe (COVID-19 pandemic: An innovative, safe and effective bio-decontamination technology for non-toxic removal of biological agents, including coronavirus)

Período documentado: 2021-08-01 hasta 2023-01-31

Resumen del contexto y de los objetivos generales del proyecto

Aquila Bioscience Ltd. (ABL) is a Biomedical Research & Development SME which has developed an innovative Pathogen Capture Technology (PCT) that uses natural biomolecules to safely capture and remove pathogens.
ABL has developed a unique pilot product, the ABD Device, a cellulose based decontamination wipe that incorporates natural binders that can capture and remove all pathogens including viruses, bacteria, fungi and their mutants in a safe and effective manner. The technology consists of non-toxic chemicals that can be safely used on sensitive skin surfaces such as face, around the eyes, nose and mouth and mucosal surfaces to disinfect these ports of entry from pathogens.
Work Objectives:
• To develop the ABwipe, now referred to as the ABD Device, from a laboratory prototype to a commercial large-scale manufacturing environment.
• To obtain external verification of the efficacy of the technology from independent laboratories.
• To gain potential customer insights through pilot studies.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Lab-scale prototypes of the ABD Devices were developed and transferred successfully to an in-house manufacturing process and pilot batches of >2,000+ units have been achieved.

Pilot studies have been carried out with potential customers and the ABD Device has been well received during these review and feedback sessions.

An external laboratory, NeoVirTech, demonstrated the ability of the device to effectively capture and remove between 99.9-99.99% of SARS-CoV-2 from human skin explants.

The product has been developed to be eco-friendly as it is largely made up of biodegradeable material and environmentally safe formulation ingredients.

Despite the travel restrictions of the Covid-19 pandemic, ABL and the ABD Device have been represented at a number of national and international conferences and media articles.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Currently, all disinfection and decontamination products are based on biocides and other toxic chemicals that have harmful effects on human skin, health and the environment. The ABD Device has the potential to change this reliance on toxic chemicals and alcohol based wipes worldwide. These developments, including the proven capture of SARS-CoV-2 from human skin, are being successfully translated into new technologies that can give a competitive advantage to EU industry, save and improve the lives of its citizens and also protect the environment.

abd-device-image.jpg